EOM Pharmaceutical Holdings (EOM Pharmaceutical Holdings) EBIT per Share : $-2.97 (TTM As of Jun. 2018)

View and export this data going back to 2006. Start your Free Trial

What is EOM Pharmaceutical Holdings EBIT per Share?

EOM Pharmaceutical Holdings's EBIT per Share for the three months ended in Jun. 2018 was $-0.07. Its EBIT per Share for the trailing twelve months (TTM) ended in Jun. 2018 was $-2.97.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for EOM Pharmaceutical Holdings's EBIT per Share or its related term are showing as below:

IMUC's 3-Year EBIT Growth Rate is not ranked ^*
in the Biotechnology industry.
Industry Median: 3.6
* Ranked among companies with meaningful 3-Year EBIT Growth Rate only.

EOM Pharmaceutical Holdings's EBIT for the three months ended in Jun. 2018 was $-0.31 Mil.

EOM Pharmaceutical Holdings EBIT per Share Historical Data

The historical data trend for EOM Pharmaceutical Holdings's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

EOM Pharmaceutical Holdings EBIT per Share Chart

EOM Pharmaceutical Holdings Annual Data

Trend

Dec08

Dec09

Dec10

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

EBIT per Share

Get a 7-Day Free Trial

-69.56

-62.52

-58.06

-74.19

-9.33

EOM Pharmaceutical Holdings Quarterly Data
	Sep13	Dec13	Mar14	Jun14	Sep14	Dec14	Mar15	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18
EBIT per Share	Get a 7-Day Free Trial															-10.20	-2.55	-0.10	-0.25	-0.07

EOM Pharmaceutical Holdings EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

EOM Pharmaceutical Holdings's EBIT per Share for the fiscal year that ended in Dec. 2017 is calculated as

	EBIT per Share		(A: Dec. 2017 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-13.429	/	1.440
=	-9.33

EOM Pharmaceutical Holdings's EBIT per Share for the quarter that ended in Jun. 2018 is calculated as

	EBIT per Share		(Q: Jun. 2018 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-0.307	/	4.191
=	-0.07

EBIT per Share for the trailing twelve months (TTM) ended in Jun. 2018 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.97

EOM Pharmaceutical Holdings (OTCPK:IMUC) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

EOM Pharmaceutical Holdings EBIT per Share Related Terms

Thank you for viewing the detailed overview of EOM Pharmaceutical Holdings's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

EOM Pharmaceutical Holdings (EOM Pharmaceutical Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » EOM Pharmaceutical Holdings Inc (OTCPK:IMUC) » Definitions » EBIT per Share

Comparable Companies

Traded in Other Exchanges

N/A

Address

136 Summit Avenue, Suite 100, Montvale, NJ, USA, 07645

Website

https://www.eompharma.com

EOM Pharmaceutical Holdings Inc is focused on developing novel immunomodulatory and retinal disease drug agents to address a range of inflammatory, viral, retinal, and other diseases. Its product candidate includes dual-acting broad-spectrum immunomodulator EOM613, which has the potential to treat cancer cachexia and rheumatoid arthritis, and its advanced formulation of EOM147 is being studied to treat serious retinal diseases without the need for intraocular injection.

Executives

Andrew Gengos	director	21900 BURBANK BOULEVARD, 3RD FLOOR, WOODLAND HILLS CA 91367
Gary Titus	director, officer: Chairman and Secretary	SCICLONE PHARMACEUTICALS, INC., 950 TOWER LANE, SUITE 900, FOSTER CITY CA 94404-2125
Anthony Gregg Lapointe	director	PO BOX 83216, GAITHERSBURG MD 20883-3216
Mark A Schlossberg	director	C/O IMPAX LABORATORIES, INC., 30831 HUNTWOOD AVENUE, HAYWARD CA 94544
Rahul Singhvi	director	246 HOLLY DRIVE, CHALFONT PA 18914
Helen Susan Kim	director	3832 BAY CENTER PLACE, HAYWARD CA 94545
Richard Chin	director	C/O OXIGENE, INC., 230 THIRD AVENUE, WALTHAM MA 02451
Richard Cowell	director	7840 VIRGINIA OAK DRIVE, GAINSVILLE VA 20155
James G. Bender	officer: VP, Product Development & Mfg.	112 WEST 34TH STREET, 17TH FLOOR, NEW YORK NY 10120
Manish Singh	director, officer: President & CEO	21900 BURBANK BOULEVARD, 3RD FLOOR, WOODLAND HILLS CA 91367
Jacqueline Brandwynne	director	649 STONE CANYON ROAD, LOS ANGELES CA 90077